Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

NCT ID: NCT00312195

Last Updated: 2012-09-10

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

267 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-03-31

Study Completion Date

2001-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10 and 20) in comparison to matching placebo transdermal system in subjects with chronic nonmalignant pain syndromes currently controlled by oral opioids. The double-blind treatment intervention duration is 2 weeks during which time supplemental analgesic medication (acetaminophen) will be provided to all subjects in addition to study drug.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Non-malignant Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Chronic pain opioid transdermal Butrans™ [BTDS]

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BTDS (5, 10 or 20)

Buprenorphine transdermal patch

Group Type EXPERIMENTAL

Buprenorphine transdermal patch

Intervention Type DRUG

Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.

Placebo to match BTDS

Placebo to match buprenorphine transdermal patch

Group Type PLACEBO_COMPARATOR

Placebo to match BTDS

Intervention Type DRUG

Placebo to match buprenorphine transdermal patch applied for 7-day wear.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Buprenorphine transdermal patch

Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.

Intervention Type DRUG

Placebo to match BTDS

Placebo to match buprenorphine transdermal patch applied for 7-day wear.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Butrans™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 2 month's history of nonmalignant pain, currently in stable pain control on opioid therapy.
* Good, very good or excellent pain control on current opioid therapy.
* Willing and able to use a telephone interactive voice response service.

Exclusion Criteria

* Currently receiving daily morphine or oxycodone monotherapy.
* Scheduled for surgery of the disease site (eg, major joint replacement surgery), or any other major surgery, which would fall within the study period.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Napp Pharmaceuticals Limited

INDUSTRY

Sponsor Role collaborator

Purdue Pharma LP

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hawthorne and York

Phoenix, Arizona, United States

Site Status

Arizona Research Center Inc

Phoenix, Arizona, United States

Site Status

Clinical Research Consultants Inc

Trumbull, Connecticut, United States

Site Status

Tampa Bay Medical Research Inc

Clearwater, Florida, United States

Site Status

Clinical Research of South Florida

Coral Gables, Florida, United States

Site Status

University Clinical Research Deland

DeLand, Florida, United States

Site Status

University Clinical Research Inc,

Pembroke Pines, Florida, United States

Site Status

Gold Coast Research LLC

Plantation, Florida, United States

Site Status

Gold Coast Research LLC

Tamarac, Florida, United States

Site Status

Family Medicine Associates

Evansville, Indiana, United States

Site Status

Pain Management and Rehabilitation

Terre Haute, Indiana, United States

Site Status

Southeastern Center for Headache and Pain

Crestview Heights, Kentucky, United States

Site Status

Westside Family Medical Center PC

Kalamazoo, Michigan, United States

Site Status

The Arthritis Clinic

Charlotte, North Carolina, United States

Site Status

Cornerstone Research Care

High Point, North Carolina, United States

Site Status

ALL-TRIALS Clinical Research LLC

Winston-Salem, North Carolina, United States

Site Status

Private Practice

Chardon, Ohio, United States

Site Status

Summit Research Solutions

Memphis, Tennessee, United States

Site Status

Radiant Research

Austin, Texas, United States

Site Status

Wasatch Clinical Research

Salt Lake City, Utah, United States

Site Status

Clinical Research Management

New Berlin, Wisconsin, United States

Site Status

Whiteabbey Health Centre

Newtownabbey, Belfast, United Kingdom

Site Status

Antrim Coast Fundholding Group

Lame, Co Antrim, United Kingdom

Site Status

Portglenone Health Centre

Portglenone, CO Antrim, United Kingdom

Site Status

Garden Street Surgery

Magherafelt, Co Derry, United Kingdom

Site Status

Springhill Surgery

Bangor, Co Down, United Kingdom

Site Status

Bennett Road Surgery

Keresley End, Coventry, United Kingdom

Site Status

Little Common Surgery

Bexhill-on-Sea, E Sussex, United Kingdom

Site Status

Old Town Surgery

Bexhill-on-Sea, E Sussex, United Kingdom

Site Status

Roebuck House Surgery

Hastings, E Sussex, United Kingdom

Site Status

Leslie Surgery

Glenrothes, Fife, United Kingdom

Site Status

Valleyfield Health Centre

High Valleyfield, Fife, United Kingdom

Site Status

Townhead Health Centre

Glasgow, Glasgow, United Kingdom

Site Status

Castlemilk Health Centre

Glasgow, Glasgow, United Kingdom

Site Status

Ashvale Health Centre

Aldershot, Hants, United Kingdom

Site Status

The Academy Medical Practice

Coatbridge, Lanarkshire, United Kingdom

Site Status

Sanbury Health Centre Group Practice

Sunbury-on-Thames, Middx, United Kingdom

Site Status

Houston Surgery

Houston, Renfrewshire, United Kingdom

Site Status

The Burns Practice

Doncaster, S Yorkshire, United Kingdom

Site Status

Grosvenor Medical Centre

Royal Tunbridge Wells, W Sussex, United Kingdom

Site Status

Gables Medical Section

Coventry, Warwickshire, United Kingdom

Site Status

The Ridge Medical Practice, Great Horton

Bradford, West Yorkshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BUP3201

Identifier Type: -

Identifier Source: org_study_id